RTP Mobile Logo

This activity is intended for medical oncologists, gynecologic oncologists, radiation oncologists, oncology fellows, oncology nurses and other healthcare providers involved in the treat¬ment of ovarian cancer.

In 2018, it is estimated that 22,240 new cases of ovarian cancer will be diagnosed in the United States and 14,070 deaths from this disease will occur. Although advancing knowledge has been hindered by substantial disease heterogeneity and uncertainties about tumor tissues of origin, a new era in the management of ovarian cancer has arrived, fueled by an increased understanding of the biologic underpinnings of tumor development and progression, especially in epithelial tumors, the most common subtype. The past few years have seen the approvals of several first-in-class PARP inhibitors for the treatment of ovarian cancer, and the emergence of a handful of extremely promising data sets is stimulating significant enthusiasm in the expectation that several more novel approaches may soon become available to practicing clinicians. This availability challenges treating physicians and other cancer clinicians to attain the confidence and competence necessary to both effectively identify patients appropriate for treatment and safely integrate these agents into routine clinical practice. Educational endeavors are therefore needed to increase awareness of novel and emerging therapies and shed light on their unique characteristics, effectiveness and propensity to cause side effects. This activity presents the perspectives of clinical investigators on key challenges and controversies surrounding how recently approved and emerging agents and strategies can be optimally and safely integrated into the care of patients with advanced ovarian cancer.


  • Evaluate faculty recommendations for initial systemic and maintenance therapies for patients in their first platinum-sensitive relapse who have mild to moderate neuropathy, and consider this information in the care of patients with ovarian cancer.
  • Review faculty preferences regarding the use of bevacizumab as part of initial and maintenance therapy recommendations for patients with ovarian cancer who have experienced disease relapse after optimal debulking surgery and chemotherapy.
  • Compare and contrast faculty preferences for the use of PARP inhibitors as maintenance therapy for patients with and without germline BRCA mutations.

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CME credit is no longer available for this issue

This CME activity consists of a text component.
CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Robert A Burger, MD
Professor, Department of Obstetrics and Gynecology
Director of Clinical Research and Fellowship Program
Division of Gynecologic Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Gradalis Inc, Janssen Biotech Inc, Morphotek Inc, Tesaro Inc, Vascular Biogenics Ltd.

Jonathan A Ledermann, MD
Professor of Medical Oncology
Clinical Director
University College London (UCL) Cancer Institute
Director, Cancer Research UK and UCL Cancer Trials Centre
London, United Kingdom

Academic Grant and Consulting Agreement: AstraZeneca Pharmaceuticals LP; Advisory Committee and Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Pfizer Inc.

Joyce F Liu, MD, MPH
Assistant Professor of Medicine
Gynecologic Oncology Program
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: AstraZeneca Pharmaceuticals LP, Tesaro Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

Mansoor Raza Mirza, MD
Medical Director, Nordic Society of Gynecologic Oncology
Chief Oncologist, Department of Oncology
Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark

Board of Directors: Karyopharm Therapeutics, Metamark Genetics Inc, Sera Prognostics Inc; Consulting Agreements: Advaxis Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Cerulean Pharma Inc, Clovis Oncology, Genmab, Karyopharm Therapeutics, Novocure, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc.

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Advisory Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc.

David M O’Malley, MD
Director, Clinical Research Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James Cancer Center
Columbus, Ohio

Advisory Committee: Amgen Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, Roche Laboratories Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: AstraZeneca Pharmaceuticals LP, Baxalta Inc, Clovis Oncology, Eisai Inc, Genentech, Merck, Roche Laboratories Inc, Takeda Oncology, Tesaro Inc, Vascular Biogenics Ltd. Data and Safety Monitoring Board: Abbott Laboratories.

Robert M Wenham, MD, MS
Senior Member and Chair, Department of Gynecologic Oncology
Director of GYN Cancer Research
Program of Chemical Biology and Molecular Medicine
Moffitt Cancer Center
Tampa, Florida

Advisory Committee and Speakers Bureau: Clovis Oncology, Genentech, Tesaro Inc; Contracted Research: Merck.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, ImmunoGen Inc and Tesaro Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2018
Expiration date: June 2019